» Articles » PMID: 38204966

Screening of Topical Formulation Excipients for Epithelial Toxicity in Cancerous and Non-cancerous Cell Lines

Overview
Journal EXCLI J
Specialty Biology
Date 2024 Jan 11
PMID 38204966
Authors
Affiliations
Soon will be listed here.
Abstract

Chemical excipients used in topical formulations may be toxic to living skin cells. Here, we compared the toxicity of some common solubilizing excipients against human melanoma cells, human keratinocytes (HaCaT) and primary skin fibroblasts (FB) as examples of cancerous, immortalized and primary human skin cells, often used as experimental models representative of conditions. Two distinct endpoint assays (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet (CV)) were used. The mechanism of cell death after excipient exposure was assessed through Reactive Oxygen Species (ROS) production, cell membrane integrity and cell cycle progression. Results showed that the surfactants, Labrasol®, Labrafil® and Transcutol®, were less toxic than Triton X-100 (a model irritant) in all cell types whereas the oil, Labrafac®, was non-toxic. The human melanoma WM164 cell line showed the greatest sensitivity toward cytotoxicity after chemical exposure, while the other cell lines were more resistant. The relative excipient cytotoxicity responses observed in the MTT and CV assays were comparable and similar trends were seen in their estimated 50 % inhibitory concentration (IC) values. DNA fragmentation by flow cytometry after exposing the cells to IC concentrations of the excipients showed negligible apoptotic populations. ROS production was increased in all cell types after toxic exposure; however, ROS elevation did not lead to apoptosis. The toxicity profiles of each excipient are not only relevant to their use in formulating safe topical products but also in the potential synergistic efficacy in the topical treatment of melanoma.

Citing Articles

Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis.

Balogh B, Peto A, Haimhoffer A, Sinka D, Kosa D, Feher P Gels. 2024; 10(11).

PMID: 39590031 PMC: 11594086. DOI: 10.3390/gels10110675.

References
1.
Duncan R, Ferruti P, Sgouras D, Ranucci E, Bignotti F . A polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments. J Drug Target. 1994; 2(4):341-7. DOI: 10.3109/10611869409015915. View

2.
Al Emran A, Marzese D, Ravindran Menon D, Stark M, Torrano J, Hammerlindl H . Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 2018; 9(9):8206-8222. PMC: 5823586. DOI: 10.18632/oncotarget.23654. View

3.
Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G . ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020; 52(2):192-203. PMC: 7062874. DOI: 10.1038/s12276-020-0384-2. View

4.
Charmeau-Genevois C, Sarang S, Perea M, Eadsforth C, Austin T, Thomas P . A simplified index to quantify the irritation/corrosion potential of chemicals - Part I: Skin. Regul Toxicol Pharmacol. 2021; 123:104922. DOI: 10.1016/j.yrtph.2021.104922. View

5.
Andersen M, Krewski D . Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci. 2008; 107(2):324-30. DOI: 10.1093/toxsci/kfn255. View